Abstract
The lack of effective treatments for heart failure with preserved ejection fraction (HFpEF) represents a large and growing unmet need in cardiology today. A critical obstacle to therapeutic innovation in HFpEF has been the absence of animal models that accurately recapitulate the complexities of the human disease. Here we propose that more comprehensive multi-organ system and functional phenotyping of preclinical models is essential if we are to maximize our chances of discovering and validating novel targets for effective therapeutic development in HFpEF.